Title of article :
Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)
Author/Authors :
Moreno، نويسنده , , Marيa and Mol، نويسنده , , Berber M. and Mensdorff-Pouilly، نويسنده , , Silvia von and Verheijen، نويسنده , , René H.M. and von Blomberg، نويسنده , , B.Mary E. and van den Eertwegh، نويسنده , , Alfons J.M. and Scheper، نويسنده , , Rik J. and Bontkes، نويسنده , , Hetty J. and Scheper، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Abstract :
huHMFG-1 (AS1402) is a humanised IgG1 against MUC1, which exerts tumour cell killing through antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells. Here, we explored the capacity of invariant NKT (iNKT) cells, which are known to activate NK cells, and toll-like receptor (TLR) ligands which activate both iNKT and NK cells, to enhance huHMFG-1-ADCC. Addition of iNKT cells, as well as TLR2/6, 7, 8 and 9 agonists to PBMC improved the efficacy of huHMFG-1. These results suggest that transfer of ex vivo expanded iNKT cells or TLR agonist treatment may improve the efficacy of NK cell-mediated antibody-based tumour immunotherapies.
Keywords :
human , Invariant NKT cells , Toll-like receptor , NK cells , ADCC
Journal title :
Cancer Letters
Journal title :
Cancer Letters
